Researchers identify B cell-rich diabetic kidney disease subgroup and validate plasma protein signature
Updated
Updated · BIOENGINEER.ORG · Apr 29
Researchers identify B cell-rich diabetic kidney disease subgroup and validate plasma protein signature
6 articles · Updated · BIOENGINEER.ORG · Apr 29
A Nature study of over 240 DKD patients found about 8.4% have a B cell-predominant subtype linked to faster kidney failure progression and validated a 14-protein plasma signature in 3,300 UK Biobank diabetics.
This B+ subgroup shows organized tertiary lymphoid structures and unique immune markers, enabling non-invasive risk stratification and outperforming traditional kidney failure risk models in predicting renal decline.
The discovery highlights adaptive immunity's role in DKD and opens new avenues for B cell-targeted therapies, representing a paradigm shift in understanding and managing diabetic kidney disease.
Could targeting B cells, a new culprit in kidney disease, halt progression for millions with diabetes?
This new kidney map found hidden immune structures. What other diseases could this technology unmask?
A new blood test predicts kidney failure years in advance. How will this change diabetes care?
With a new plasma test for DKD, are we entering an era of precision nephrology?
Can the new APOL1 risk score finally address kidney disease disparities in African ancestry populations?